Monoclonal antibodies has been very effective in cancers with a known target, such as CD20-positive lymphoma (Rituxan) or Her2 positive breast cancer (Herceptin). In multiple myeloma no monoclonal antibodies has been approved as yet.Elotuzumab is a humanized monoclonal antibody that targets a cell-surface protein called CS1 that is highly expressed (90%) on multiple myeloma cells. The drug is able to induce cell breakdown and cell death.
The ELOQUENT-1 trial hase (III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma) is currently available at PSMG. See at clinicaltrials.gov click here
For more information call Irene at 562-590-0345